JO2978B1 - MGLU2 aids - Google Patents

MGLU2 aids

Info

Publication number
JO2978B1
JO2978B1 JO2010439A JOP20100439A JO2978B1 JO 2978 B1 JO2978 B1 JO 2978B1 JO 2010439 A JO2010439 A JO 2010439A JO P20100439 A JOP20100439 A JO P20100439A JO 2978 B1 JO2978 B1 JO 2978B1
Authority
JO
Jordan
Prior art keywords
mglu2 agonists
mglu2
agonists
schizophrenia
depression
Prior art date
Application number
JO2010439A
Other languages
Arabic (ar)
English (en)
Inventor
الين مون جيمس
بريتو لورديس
تابودا مارتينز لورينا
مونتيرو سالجادو كارلوس
ويليام شو بروس
Original Assignee
ايلي ليلي اند كومباني
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42026702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO2978(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ايلي ليلي اند كومباني filed Critical ايلي ليلي اند كومباني
Application granted granted Critical
Publication of JO2978B1 publication Critical patent/JO2978B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JO2010439A 2009-12-21 2010-12-09 MGLU2 aids JO2978B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09382290 2009-12-21
US30523910P 2010-02-17 2010-02-17

Publications (1)

Publication Number Publication Date
JO2978B1 true JO2978B1 (en) 2016-03-15

Family

ID=42026702

Family Applications (1)

Application Number Title Priority Date Filing Date
JO2010439A JO2978B1 (en) 2009-12-21 2010-12-09 MGLU2 aids

Country Status (35)

Country Link
US (1) US8318184B2 (enExample)
EP (1) EP2516406B1 (enExample)
JP (1) JP5779190B2 (enExample)
KR (1) KR101395356B1 (enExample)
CN (1) CN102695701B (enExample)
AR (1) AR079343A1 (enExample)
AU (1) AU2010340039B2 (enExample)
BR (1) BR112012017188B1 (enExample)
CA (1) CA2784667C (enExample)
CR (1) CR20120322A (enExample)
CY (1) CY1114880T1 (enExample)
DK (1) DK2516406T3 (enExample)
DO (1) DOP2012000173A (enExample)
EA (1) EA020229B1 (enExample)
EC (1) ECSP12011989A (enExample)
ES (1) ES2435651T3 (enExample)
HN (1) HN2012001160A (enExample)
HR (1) HRP20131052T1 (enExample)
IL (1) IL220011A (enExample)
JO (1) JO2978B1 (enExample)
MA (1) MA33824B1 (enExample)
MX (1) MX2012007332A (enExample)
MY (1) MY160618A (enExample)
NZ (1) NZ600305A (enExample)
PE (1) PE20121688A1 (enExample)
PH (1) PH12012501253A1 (enExample)
PL (1) PL2516406T3 (enExample)
PT (1) PT2516406E (enExample)
RS (1) RS53063B (enExample)
SG (1) SG181836A1 (enExample)
SI (1) SI2516406T1 (enExample)
TN (1) TN2012000281A1 (enExample)
TW (1) TWI477490B (enExample)
UA (1) UA107684C2 (enExample)
WO (1) WO2011084437A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3533797B1 (en) 2010-02-17 2023-12-20 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN103209954B (zh) * 2010-11-18 2015-09-02 伊莱利利公司 作为mGluR2/3拮抗剂的4-取代的-3-苄氧基-双环[3.1.0]己烷化合物
AR083845A1 (es) * 2010-11-18 2013-03-27 Lilly Co Eli COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3
KR101598679B1 (ko) 2011-06-17 2016-02-29 일라이 릴리 앤드 캄파니 mGlu2 수용체 효능제로서의 비시클로(3.1.0)헥산-2,6-디카르복실산 유도체
AR089718A1 (es) 2012-02-01 2014-09-10 Lilly Co Eli AGONISTAS DE mGlu2/3
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
PL3096790T3 (pl) * 2014-01-21 2020-01-31 Janssen Pharmaceutica, N.V. Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie
NZ735973A (en) 2015-04-01 2023-06-30 Akebia Therapeutics Inc Compositions and methods for treating anemia
WO2021216530A1 (en) 2020-04-20 2021-10-28 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576323A (en) * 1993-12-03 1996-11-19 Eli Lilly And Company Excitatory amino acid receptor antagonists
GB9605429D0 (en) * 1995-11-16 1996-05-15 Lilly Co Eli Excitatory amino acid receptor antagonists
US5688826A (en) * 1995-11-16 1997-11-18 Eli Lilly And Company Excitatory amino acid derivatives
ZA983930B (en) 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
WO2002055485A1 (en) * 2001-01-11 2002-07-18 Eli Lilly And Company Prodrugs of excitatory amino acids
US7256217B2 (en) * 2001-01-11 2007-08-14 Eli Lilly And Company Prodrugs of excitatory amino acids
WO2002068380A1 (en) * 2001-02-22 2002-09-06 Eli Lilly And Company Synthetic excitatory amino acids
HRP20041179B1 (hr) * 2002-06-11 2012-11-30 Eli Lilly And Company Prekursorski oblici lijekova za aminokiseline s pobuđivačkom aktivnosti
US7381746B2 (en) * 2003-06-26 2008-06-03 Taisho Pharmaceutical Co., Ltd. 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative
CN103209954B (zh) * 2010-11-18 2015-09-02 伊莱利利公司 作为mGluR2/3拮抗剂的4-取代的-3-苄氧基-双环[3.1.0]己烷化合物
AR083845A1 (es) * 2010-11-18 2013-03-27 Lilly Co Eli COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3

Also Published As

Publication number Publication date
BR112012017188A8 (pt) 2016-10-04
AU2010340039A1 (en) 2012-08-09
US8318184B2 (en) 2012-11-27
MA33824B1 (fr) 2012-12-03
HRP20131052T1 (hr) 2013-12-06
PE20121688A1 (es) 2012-12-05
BR112012017188A2 (pt) 2016-03-22
JP5779190B2 (ja) 2015-09-16
SI2516406T1 (sl) 2013-11-29
ES2435651T3 (es) 2013-12-20
BR112012017188B1 (pt) 2021-06-22
IL220011A (en) 2014-03-31
MY160618A (en) 2017-03-15
EA020229B1 (ru) 2014-09-30
NZ600305A (en) 2014-01-31
US20110152334A1 (en) 2011-06-23
TN2012000281A1 (en) 2013-12-12
HN2012001160A (es) 2015-08-24
CN102695701A (zh) 2012-09-26
KR20120094056A (ko) 2012-08-23
PL2516406T3 (pl) 2014-03-31
EP2516406B1 (en) 2013-09-18
HK1171228A1 (en) 2013-03-22
EA201290558A1 (ru) 2012-12-28
ECSP12011989A (es) 2012-07-31
CA2784667C (en) 2014-11-18
TW201144290A (en) 2011-12-16
JP2013514974A (ja) 2013-05-02
IL220011A0 (en) 2012-07-31
AU2010340039B2 (en) 2014-03-20
PT2516406E (pt) 2013-10-10
EP2516406A1 (en) 2012-10-31
DOP2012000173A (es) 2012-11-30
WO2011084437A1 (en) 2011-07-14
AR079343A1 (es) 2012-01-18
CY1114880T1 (el) 2016-12-14
DK2516406T3 (da) 2013-10-14
RS53063B (sr) 2014-04-30
UA107684C2 (xx) 2015-02-10
KR101395356B1 (ko) 2014-05-14
TWI477490B (zh) 2015-03-21
CR20120322A (es) 2012-07-10
MX2012007332A (es) 2012-07-20
PH12012501253A1 (en) 2014-08-01
CA2784667A1 (en) 2011-07-14
CN102695701B (zh) 2014-10-01
SG181836A1 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
MY160618A (en) Mglu2 agonists
PH12012501355A1 (en) Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor
MX340555B (es) Anticuerpos contra il-18r1 y usos de los mismos.
TN2011000673A1 (en) Bace inhibitors
UA104459C2 (uk) Антитіла проти fgfr3 і способи їх застосування
MX2013011479A (es) Anticuerpos anti-fgfr4 y metodos de uso.
MX336001B (es) Anticuerpos anti-axl y metodos de uso.
MX2013015311A (es) Polipeptidos de enlace de pcsk9 y metodos de uso.
MX2011011925A (es) Anticuerpos triespecificos o tetraespecificos.
PH12013500500A1 (en) Fused heteroaryls and their uses
MX2011007576A (es) Articulos absorbentes reusables para llevar puestos con sistema secundario de fijacion.
PH12014500841B1 (en) ANTI-HtrA1 ANTIBODIES AND METHODS OF USE
IN2014CN04014A (enExample)
MX2012011829A (es) Anticuerpos de anti-poliubiquitina y metodos de uso.
MY161868A (en) Anti-bv8 antibodies and uses thereof
MY143269A (en) Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder
EP2533796A4 (en) METHOD FOR THE TREATMENT OF GLUCOSE TISSUE CHANGES
PH12012501547A1 (en) Methods of preparing thiazolidines
UA41660U (en) Use of jacton and mexidol as actoprotector
UA44978U (en) 2,8-dimethyl-3-dymethylaminomethylquinolione-4-on possessing anxiolytic and antiamnestic activities
EA201391700A1 (ru) АГОНИСТЫ РЕЦЕПТОРА mGlu2
UA35660U (en) Use of antihomotoxic preparations as cytoprotectors
UA52379U (ru) Применение ЛИПИНА в качестве средства фригопротекторного действия
UA52376U (ru) Применение КОРВИТИНА в качестве средства фригопротекторного действия
AU329266S (en) Clip